China's Biotech Moment Ignites a 60% Stock Rally That Beats AI
The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal.
'China biotech is no longer just an emerging story — unlike 10 years ago — it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.'
The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation. The rally in the sector this year outpaces the 17% gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January.
A major reason for the share gains were two mega-sized licensing deals. Pfizer Inc. said on May 19 it had agreed to pay a record $1.25 billion to license an experimental cancer drug from China's 3SBio Inc., and also invest $100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb Co. said it would pay Germany's BioNTech SE as much as $11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus Inc. in 2023.
Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283%, topping a Bloomberg gauge of global biotech stocks. RemeGen Co., which develops antibody drugs, has climbed more than 270% after saying it was approached by multinational pharmaceutical firms for potential licensing deals.
China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to $36.9 billion. That amount made up more than half the global total of $67.5 billion.
Chinese biotech companies are having 'their own DeepSeek moment,' said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said.
Investor interest in biotech — which involves the use living organisms to make medicines and other products — can be seen in the big runup at recent initial public offerings.
Shares of Duality Biotherapeutics Inc., which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on April 15. Jiangsu Hengrui Pharmaceuticals Co., the nation's largest drugmaker by market value, saw its stock jump 25% on debut May 23, even after being issued at the top end of the marketed range. Duality has now risen 189% since its IPO, while Jiangsu has gained 31%.
Still, some say the rally may be getting stretched.
'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America Corp. analysts including Ethan Cui in Hong Kong wrote in a research note this month.
Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote.
While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong.
Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms.
Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York.
With assistance from Dong Lyu.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fibre2Fashion
29 minutes ago
- Fibre2Fashion
Profit warnings by UK-listed firms up 20% YoY in Q2 2025: EY-Parthenon
UK-listed businesses issued 59 profit warnings in the second quarter (Q2) this year—a 20-per cent rise year on year (YoY), according to an EY-Parthenon report, which revealed that 46 per cent of those warnings cited policy change and geopolitical uncertainty as a leading factor—the highest percentage ever recorded for this cause and up from just 4 per cent during the same period last year. Nearly a fifth (19 per cent) of such businesses issued at least one warning in the last 12 months. A profit warning is a public statement issued by a company to inform its shareholders and the public that its financial performance is expected to be lower than previously anticipated. UK-listed businesses issued 59 profit warnings in Q2 2025â€'a 20-per cent rise YoY, an EY-Parthenon report said. Close to a fifth issued at least one warning in the last 12 months. Forty-six per cent of those warnings cited policy change and geopolitical uncertainty as a top factor. Two-fifths of those cited contract and order cancellations or delays, while 34 per cent cited tariff-related impacts. Profit warnings citing contract and order cancellations or delays remained at a record level in Q2 (40 per cent), while 34 per cent cited tariff-related impacts, including weaker demand, supply chain disruption, and exchange-rate volatility. Retail was among the sectors with the highest number of profit warnings during the second quarter. EY-Parthenon is the strategy consulting arm of Ernst & Young (EY), focusing on transformative strategy and transactions. Fibre2Fashion News Desk (DS)
Mint
an hour ago
- Mint
Oil Rises as Trade Talk Progress Undercuts Eased Venezuela Curbs
(Bloomberg) -- Oil gained as technical support turbocharged a rally sparked by progress in international trade talks, undercutting a US move to restore Chevron Corp.'s ability to pump oil in Venezuela. West Texas Intermediate climbed 1.2% to settle above $66 a barrel, following four sessions of declines. The European Union and the US are progressing toward a deal that would set a 15% tariff for most imports, similar to the one President Donald Trump struck with Japan. That would be a smaller rate than investors feared, with the US president earlier threatening a 30% levy on most goods if an agreement wasn't reached by Aug. 1. The US benchmark also pushed through its 50-day moving average, triggering a spate of technical buying just ahead of the market's close. The technical boost erased an earlier slide spurred by the Trump administration's decision to let Chevron resume pumping oil in Venezuela, raising the prospect of increased supplies flooding into a market already facing the threat of oversupply. US imports of Venezuelan crude have ground to a halt, down from 300,000 barrels a day in January, according to Matt Smith, Americas lead oil analyst at market intelligence firm Kpler. Still, energy products from the Latin American country have already accounted for 15% of waterborne deliveries to the US Gulf Coast this year, he added. 'The revocation of Chevron's license has been to the benefit of China, given barrels have been redirected there,' Smith said. 'Perhaps the realization of this, along with the supply issues on the US Gulf Coast, has been a driver behind the reversal of the decision.' Oil prices have been in a holding pattern this month, with tightness in global diesel markets offset by expectations of a deluge of crude supply from OPEC as the group raises production quotas. While diesel inventories in the US are starting to build back up, they're still at the lowest seasonal level since 1996. The relative calm comes after a period of choppy trading that Norwegian oil giant Equinor ASA said Wednesday had hurt its energy trading business. France's TotalEnergies SE painted a dour outlook Thursday, saying the oil market is facing 'abundant supply that is fueled by OPEC 's decision to unwind some voluntary production cuts.' To get Bloomberg's Energy Daily newsletter in your inbox, click here. More stories like this are available on
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
'UK is back on world stage': Keir Starmer after trade deal with India
The trade deal comes at a time when US President Donald Trump's tariff policies continue to disrupt global trade Bloomberg The UK has restored its international standing after years of 'performative' politics under successive Conservative governments, Labour Prime Minister Keir Starmer said in an interview after sealing a long-sought trade deal with India on Thursday. The trade deal — the biggest struck by Britain since Brexit — will cut the vast majority of India's tariff lines for the UK, helping exports from Scotch whisky to cars. But speaking at his Chequers country retreat after meeting with Indian Premier Narendra Modi, Starmer said the agreement didn't mark the limit of the UK's ambition, and would provide a baseline of cooperation to build on for the two countries. 'We have re-established the place and position of the UK on the world stage,' Starmer told Bloomberg in his only interview with a major publication to mark crystallisation of the pact, referring also to increased cooperation with the European Union and a trade pact with the US. Now, 'we're seen as a country which other countries want to be working with and delivering with.' The deal signed earlier Thursday by the Indian and British trade ministers eliminated or reduced a swath of tariffs and lifted other barriers to commerce. The pact came after three years of intense negotiations touching on thorny topics such as visas, and tax breaks. The two nations concluded talks in May, completing Britain's biggest trade deal since Brexit and India's most significant such agreement to date. 'This isn't merely paving the way for economic partnership but is also a blueprint for our shared prosperity,' Modi said earlier Thursday, speaking alongside Starmer at Chequers. In an interview with Bloomberg on Thursday evening, Modi's trade minister, Piyush Goyal, said the deal will 'open the doors for more robust and resilient supply chains,' as well as encouraging 'greater investments because of the stable and predictable business environment.' 'It's a win win for both UK and India,' he said. A separate bilateral investment treaty is still being negotiated between the UK and India, which could include more controversial elements such as a provision which allows investors to sue either government if they believe a policy change has unfairly affected their profits. 'I do hope we will get that also across the hump soon,' Goyal said of the treaty, declining to discuss the sticking points. The trade deal comes at a time when US President Donald Trump's tariff policies continue to disrupt global trade, and Starmer told Bloomberg that it marked 'a real statement of intent as to how close we want our two countries to be as we go forward in an uncertain world.' He added that he and Modi had already begun to discuss which areas they could build on. Starmer, whose Labour Party was elected to power a year ago, also made a jibe at his Tory predecessors Boris Johnson and Rishi Sunak — both of whom set and missed their own deadlines for agreeing a deal with India, with the former famously promising one by Diwali 2022. 'Serious, pragmatic, respectful diplomacy trumps performative politics any day of the week,' Starmer said. He added that the 'quiet, serious, pragmatic, respectful way' in which he had asked officials to proceed 'achieved results compared with the noisy performance of my predecessors.' Starmer and Modi earlier attended a showcase of businesses who hoped to benefit from the trade deal. Representatives from firms including the supermarket chain Sainsbury's and family-run Spice Kitchen staffed stands under a marquee in the Chequers rose garden, and said they were excited about the opportunities for further cooperation between the UK and India. 'We import a lot from India,' said Spice Kitchen's Sanjay Aggarwal, who runs the business with his mother Shashi. 'Hopefully some of our costs will come down.' Starmer had said he 'loves to cook and loves Indian food,' Aggarwal added. For Modi, the deal reinforces his push to position India as a viable alternative for global supply chains looking to diversify. The pact — India's first major one in a decade — signals that the South Asian nation is willing to lower its barriers to attract investments as it negotiates a bilateral trade deal with the US. It will also act as a springboard for India's ongoing talks with European Union. For Starmer, the deal will be a welcome step toward his goal of boosting economic growth in the UK. While it is expected to add £4.8 billion ($6.5 billion) to the UK's annual economic output — a tiny increase to the size of the economy — Starmer's Labour government hopes successive incremental wins will help encourage investment and turn around lackluster business sentiment. With Trump due to arrive in Scotland on Friday for a personal visit during which he'll meet with Starmer, the signing comes as Britain works to flesh out the trade pact it agreed with the US. Meanwhile the New Delhi administration is racing to clinch a deal with Washington before Aug. 1, when higher tariffs are due to kick in. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
